Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I–II clinical trial

Kharaziha, Pedram; Hellström, Per M.; Noorinayer, Babak; Farzaneh, Farivar; Aghajani, Katayoun; Jafari, Fatemeh; Telkabadi, Mohammad; Atashi, Amir; Honardoost, Maryam; Zali, Mohammad Reza; Soleimani, Masoud

doi:10.1097/meg.0b013e32832a1f6c

Cited by 393 publications

(280 citation statements)

References 44 publications

Supporting

Mentioning

263

Contrasting

Unclassified

Order By: Relevance

“…These patients also showed an improvement in albumin production and liver function after 6 months of follow-up. 23 However, these findings need to be confirmed in a larger cohort of patients. The long-term efficiency and safety of MSC transplantation also needs to be determined by tracer studies.…”

Section: Therapeutic Mechanism Of Msc Transplantationmentioning

confidence: 93%

“…Experiments in a mouse model of FHF showed that MSC transplantation through the veins had a better effect than intrasplenic transplantation. 23 IMDs or FHF can be successfully treated by MSC transplantation through the portal vein, although temporary portal hypertension has been observed in some animal studies. However, in ESLD, distorted architecture, point injection and portal infusion may result in pulmonary embolism and long-term portal hypertension.…”

Section: Quality Parameters For the Application Of Mscsmentioning

confidence: 99%

See 1 more Smart Citation

Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases

Zhang

et al. 2010

Cell Mol Immunol

View full text Add to dashboard Cite

Transplantation of mesenchymal stem cells (MSCs) has been recently studied in animal models, and in clinical trials of patients with fulminant hepatic failure, end-stage liver diseases and inherited metabolic disorders. Modulatory cytokines produced by MSCs can inhibit immunocyte proliferation and migration to the liver, thereby attenuating inflammatory injury and reducing hepatocyte apoptosis. In addition, MSCs play an important role in regressing liver fibrosis and in supporting the function, proliferation and differentiation of endogenous hepatocytes under appropriate conditions. Although remarkable progress has been achieved in basic and clinical MSC studies, optimal therapeutic regimens for the clinical application of MSCs, such as optimal doses, transplantation routine and interval period for transplantation, need to be elucidated in detail. Furthermore, the long-term safety and therapeutic efficacy of MSC transplantation should be evaluated in future clinical trials. This review summarizes our current understanding of the immunomodulatory effects of MSC therapies on human liver diseases.

show abstract

Section: Therapeutic Mechanism Of Msc Transplantationmentioning

confidence: 93%

Section: Quality Parameters For the Application Of Mscsmentioning

confidence: 99%

Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases

Zhang

et al. 2010

Cell Mol Immunol

View full text Add to dashboard Cite

show abstract

“…Specifically, bone marrow derived mesenchymal stem cells (35), hematopoietic stem cells (36,37) and fetal liver progenitor/stem cells (38) have shown to improve, to a certain extent, the condition of cirrhotic patients. The latter cell type holds an enormous potential for cell/regenerative medicine therapies due to their high expansion capabilities and differentiation into hepatocytes and biliary epithelium (39).…”

Section: Cell Therapiesmentioning

confidence: 99%

Liver Regeneration and Bioengineering - The Emergence of Whole Organ Scaffolds

Baptista¹,

Vyas²,

Söker³

2012

Liver Regeneration

View full text Add to dashboard Cite

“…In autoimmune disease treatment, engraftment of MSCs improves the levels of serological markers and stabilizes renal function by preventing the appearance of serious adverse events (11). MSCs have also been widely used in many treatment trials, including stem cell-based therapies for liver cirrhosis (12), cerebral palsy (13), type I diabetes (14), multiple sclerosis (15) and graft-vs.-host disease (16). However, the effect of MSCs on lung cancer cells remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Biological functions of lung cancer cells are suppressed in co‑culture with mesenchymal stem cells isolated from umbilical cord

Chai

Bai

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Stem cell-based therapy serves a key role in clinical treatments, and mesenchymal stem cells (MSCs) have been widely used in clinical tumor therapy trials. In the present study, MSCs were isolated from umbilical cord (UC) and co-cultured with the lung cancer cell line H1299. The effects of UC-derived MSCs (UCMSCs) on H1299 cell invasion and proliferation were evaluated using a Matrigel-based Transwell assay and CCK8 assay, respectively. Apoptosis and cell cycle progression among H1299 cells were detected by flow cytometry, and kinase expression in H1299 cells was detected by western blotting. The results indicated that UCMSCs significantly inhibited H1299 cell invasion and significantly induced apoptosis of H1299 cells, but exhibited no effect on H1299 cell proliferation and cell cycle progression. It was also identified that H1299 cell expression of key kinases (AKT, phosphoinositide 3-kinase, signal transducer and activator of transcription 3 and mechanistic target of rapamycin) was significantly suppressed in the presence of UCMSCs. To the best of our knowledge, the present study demonstrates for the first time that UCMSCs have an anti-tumor effect against lung cancer cells, which may indicate that AKT/phosphoinositide 3-kinase/signal transducer and activator of transcription 3 signaling is important in the UCMSC-mediated regulation of H1299 cell functions.

show abstract

Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I–II clinical trial

Abstract: Our data show that MSCs injection can be used for the treatment of end-stage liver disease with satisfactory tolerability. Furthermore, this treatment may improve clinical indices of liver function in end-stage liver disease.

Cited by 393 publications

References 44 publications

Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases

Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases

Liver Regeneration and Bioengineering - The Emergence of Whole Organ Scaffolds

Biological functions of lung cancer cells are suppressed in co‑culture with mesenchymal stem cells isolated from umbilical cord

Contact Info

Product

Resources

About